The revised Swiss Federal Act on Data Protection (FADP) went into effectiveness September 1, 2023, and it poses significant challenges for clinical trials. The new law applies not only to trials conducted in Switzerland but also to any data processing operations within the country. It introduces severe sanctions for individuals responsible for infringements, mandates immediate...
ESMO 2023 brings together researchers, clinicians, scientists and healthcare market leaders from all over the world. The congress hosts the latest cutting-edge data, high-quality education, and innovations on the field. Accelsiors is deeply involved in the field of oncology (breast, ovarian, renal cancer, melanoma etc), and our team has designed and executed numerous trials in the...
We are marking an exciting, new milestone with the opening of Accelsiors’ Los Angeles office – a significant step in our journey to bring our services closer to our clients & partners. This investment reflects our deep commitment to our valued clients in the US. By establishing a local presence, we’re dedicated to providing tailored...
Accelsiors has joined Biocom California! This marks our dedicated focus on the US market, reinforcing our commitment with strategic investments. Thrilled to be part of this dynamic community. You can find more about our mission and values here. We know. We care. We support.
Accelsiors’ team attended the #AAIC2023! The latest evolution and clinical research results were published at the Alzheimer’s Association International Conference (AAIC) in Amsterdam. Our team was there, strengthening connections with scientists and clients, with a strong belief for a bright future of Alzheimer’s clinical research. After-conference conclusions Many promising findings for the Alzheimer...
